About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518·50 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

Age

10–17

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adolescent patients with schizophrenia, or child and adolescent patients with bipolar I disorder, manic or mixed episode

You may not be if

Patients with a co-morbid serious, uncontrolled systemic illness
Patients with a significant risk of committing suicide

The record

StatusCompleted

PhasePhase 3

Taking part325

StartedSep 2004

UpdatedAug 31, 2012

Conditions

Schizophrenia Bipolar Disorder

Where50

Local Institution
Birmingham, Alabama, United States
Local Institution
Little Rock, Arkansas, United States
Local Institution
Costa Mesa, California, United States

Clareo Health | Aripiprazole Open-Label, Safety and Tolerability Study